MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the third quarter of 2024. Third Quarter 2024 Highlights Third quarter 2024 revenue of $18.5 million, a 4% increase as compared to the third quar ...

MALVERN, Pa., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release third quarter 2024 financial and operating results prior to market open on Tuesday, November 12, 2024. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call ...

MALVERN, Pa., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced today their participation at the American Academy of Child and Adolescent Psychiatry (AACAP) in Seattle, WA, from October 14th-19th, including an oral presentation at the "Research Pipeline: New Findings on Therapeutics" session featuring data gener ...

MALVERN, Pa. and TORONTO, Oct. 4, 2024 /PRNewswire/ - Neuronetics, Inc. (NASDAQ: STIM) ("Neuronetics") and Greenbrook TMS Inc. (OTCMKTS: GBNHF) ("Greenbrook") today announced that the Ontario Superior Court of Justice (Commercial List) (the "Court") has granted an interim order (the "Interim Order") in connection with the previously announced statutory plan of arrangement under section 182 of the Business Corporations Act (Ontario) (the "Plan of Arrangement"), pursuant to which, subject to the satisfaction ...

MALVERN, Pa., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that Health Care Service Corporation (HCSC) has expanded access to TMS (transcranial magnetic stimulation) for adolescents 15 and older with major depressive disorder (MDD). This policy parallels the recent clearance by the Food and Drug Administra ...

Neuronetics, Inc. (STIM) recently announced that additional payors have updated the coverage of TMS (transcranial magnetic stimulation). This upgrade is aimed at reducing the access barriers for patients with major depressive disorder (MDD). This expanded access will help people receive treatments, such as the company's NeuroStar TMS therapy, earlier in their treatment regimen. STIM Stock Likely Trend Following the News Following the news, STIM stock fell 1.8% to 93 cents on Friday. However, the company is ...

MALVERN, Pa., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that additional payors have updated their TMS (transcranial magnetic stimulation) coverage to reduce access barriers for patients with major depressive disorder (MDD). This expanded access allows people to receive treatment such as the Company's Ne ...

Core Insights - Neuronetics, Inc. has announced enhancements to its NeuroStar Advanced Therapy and TrakStar patient data management software, focusing on improving patient communication, clinical data capture, and cybersecurity [1][2]. Company Developments - The latest upgrades aim to transform patient care practices by providing tools for more personalized, efficient, and secure treatment [2]. - Key upgrades include enhanced patient communication through automated SMS and email, secure insurance card uploads, and location-based communication management for multi-site practices [2]. - Expanded survey options in TrakStar allow for a wider range of automated clinical surveys to monitor patient well-being during and after treatment [2]. - The NeuroStar device now synchronizes critical clinical information with TrakStar, automating data tracking and improving accuracy [2]. - Security improvements include proactive updates to the Operating System to ensure encrypted patient data and communications [2][3]. Product Information - TrakStar software updates are available for all cloud-based NeuroStar providers, while NeuroStar System software updates will be rolled out throughout the year [3]. - NeuroStar Advanced Therapy is a non-drug, noninvasive treatment for mental health conditions, particularly effective for patients with major depressive disorder (MDD) who have not responded to traditional medications [4]. - NeuroStar has delivered over 6.6 million treatments, establishing itself as a leading TMS treatment for MDD in adults [4].

MALVERN, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, is proud to shine a light on the powerful stories shared through the NeuroStar Voices Portal in recognition of Suicide Prevention Month. Launched last year, the portal has become a vital platform for individuals to share their journeys of battling depression ...

Neuronetics, Inc. (STIM) recently announced a definitive agreement with Greenbrook TMS Inc. to acquire its outstanding common shares in an all-stock transaction. Following the merger's completion, Greenbrook will be able to improve its existing sites to provide the benefits of NeuroStar to any practice across the country. It will do so using Neuronetics' innovative NeuroStar platform as well as its education and training expertise. The merger agreement will help Neuronetics strengthen its position in the me ...